Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7939515 | 0.97 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL7940758 | 0.85 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL18531632 | 0.79 | — | — | |
| SCHEMBL18353931 | 0.79 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL13844236 | 0.79 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL24655048 | 0.79 | — | — | |
| SCHEMBL14820384 | 0.79 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL7931704 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL21715915 | 0.77 | — | — | |
| SCHEMBL99336 | 0.77 | CYP1A2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11612657-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220347302-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-11-03 | — | — | US | disclosed |
| US-11382979-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220175929-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2022-06-09 | — | — | US | disclosed |
| US-20170029352-A1 | PRODUCTION SYSTEM/PRODUCTION PROCESS FOR ACRYLIC ACID AND PRECURSORS THEREOF | NOVOMER, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20150306039-A1 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS | BANK OF AMERICA, N.A. | 2015-10-29 | — | — | US | disclosed |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2015-10-01 | — | — | US | disclosed |
| US-9061063-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-6248885-B1 | 1. TERT-OCTYLDI-N-PROPLYLAMINE. 2. TERT-OCTYL-N-MORPHOLINE-BORANE. | SIGMA-ALDRICH CO. | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | ALDH1A1 3904/4885 |
| US-20220175929-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | ALDH1A1 3151/4885 |
| US-11612657-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | ALDH1A1 3151/4885 |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | ALDH1A1 3151/4885 |
| US-11382979-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | ALDH1A1 3151/4885 |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | ALDH1A1 3151/4885 |
| US-20220347302-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | ALDH1A1 3151/4885 |
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | ALDH1A1 516/4885 |
| US-20170029352-A1 | PRODUCTION SYSTEM/PRODUCTION PROCESS FOR ACRYLIC ACID AND PRECURSORS THEREOF | PCCA, COASY, ALAD | ALDH1A1 520/4885 |
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | ALDH1A1 3787/4885 |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | ALDH1A1 3151/4885 |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | ALDH1A1 3151/4885 |
| US-20150306039-A1 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS | LIPA, NPC1L1, CETP | ALDH1A1 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.